Short report: Benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up

• Autor(a) principal: Andrade, Ana Lucia SS
• Data de Publicação: 2004
• Outros Autores: Martelli, Celina MT, Oliveira, Renato M., Silva, Simonne A., Aires, Andréa IS, Soussumi, Lea MT, Covas, Dimas Tadeu, Silva, Luiz S., Andrade, Joao G., Travassos, Luiz Rodolpho [UNIFESP], Almeida, Igor Correa de [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://www.ajtmh.org/content/71/5/594.abstract; http://repositorio.unifesp.br/handle/11600/42478

Data from a six-year follow-up of Trypanosoma cruzi-infected adolescents enrolled in a randomized, double-blind, clinical trial of benznidazole showed successful chemotherapy in 64.7% (95% confidence interval [CI] 50.2-78.7) and 84.7% (95% Cl = 66.8-92.9), respectively, by intention-to treat and by per protocol analysis measured by seronegativity in a chemiluminescent enzyme-linked immurbosorbent assay with a purified trypomastigote mucin antigen. No incident case of cardiomyopathy was detected by electrocardiogram assessment in this cohort of adolescents who had been infected in childhood. The persistent and consistently long-term negative serologic reactions suggest the absence of the parasite in the treated patients and reinforces the recommendation of early benznidazole chemotherapy for T. cruzi-infected infants as a public health policy in endemic areas.